Today Percepta Associates released its 2016 Protein Electrophoresis and Western Analysis, Series 3 Life Science Dashboard™ market research report which draws comparisons to key market indicator data reported in Percepta’s 2013 Series 2 Dashboard. This updated dashboard reveals an increase in growth rates for 6 of the 7 product categories surveyed compared to 2013 findings, with highest anticipated growth…read more >
Three Trends in Biotools Markets for 2011
It was a hectic close to 2010 which shows us that biotools industry is alive and healthy! Though the future economic environment for the globe remains uncertain and public funding levels for life sciences in the US may plataue of or even dip in 2011, there were several things that we noticed at Percepta that we believe will be…read more >
Bio-tool Companies Aim at Better Offering for Drug Development
In the recent few quarters Percepta has experienced an increase in demand for studies relating to better serving the pharmaceutical industry. The focus of the studies have varied considerably but the trend is evident. This tells us bio-tools companies are getting more serious about tailoring an offering to the drug discovery and development market that will resonate with the…read more >
Cell Culture Research Market Growing; New Data Projects Declining Growth in Sub Segments
New report reveals the cell culture research market is expected to grow to nearly $600 million in 2011, but experiencing declining growth across sub segments
Carlsbad, Calif. – September 7, 2010 – Today, Percepta Associates launched its Series Three Cell Culture Life Science DashboardTM market research report. Unique to this Series are comparisons and trends based on key market indicator…read more >
What Will Be The Next Big Thing?
What will be the next big thing to drive growth in the bio-tools industry? Will it be epigenetics? Gene regulation is now a focus of many drug development programs within the pharmaceutical industry. The past five years have seen the genesis of many new companies dedicating their focus to products and services tailored to monitoring gene regulation by methylation,…read more >
Branding: Defense Against Bio-tools Commoditization
We hear all the time that elements of traditional molecular biology reagent portfolios have become increasingly commoditized. Dictionary.com defines commodity as “any bulk good traded in an exchange…”. By that people generally mean that the reagent is not differentiated by anything other than price. One bag of tips or tubes is the same as the next so why pay…read more >
eMail Lists vs. eFail Lists – Do You Know the Difference?
If you are in the business of selling research products to life scientists then chances are good you have probably sent out promotional information or conducted market research using email. It is an efficient and cost effective way to reach lots of potential customers quickly. If you are using your customer lists to communicate new products or promote special…read more >
Biotools Marketing 101: When Hiring Consultants Hire Experience First
There are times each year when our clients just need a little extra help to get things done. There are a lot of reasons that this is true – internal staffing shortfalls, impending strategic planning, management pressing project time lines, initiative de jour – you name it. This of course always causes stress for the marketing manager that needs…read more >
Biotools Marketers – Got Marketing Bandwidth?
All of us at Percepta have cumulatively been involved in literally hundreds of biotools product launches in the course of our careers at various well known biotools companies. Some of these products were fabulous successes and others were fantastic flops. The flops failed for a variety of reasons but the successes all had one thing in common – they…read more >
Can Stimulus Dollars Sustain Biotools Growth?
As everyone knows, the Great Recession or 2008 and 2009 has taken its toll on most industries and the biotools supply industry is no exception. However, there is real evidence that the light at the end of the tunnel is getting a bit brighter. Stimulus dollars from the American Recovery and Reinvestment Act of 2009 have finally started to…read more >